Abstract
Rationale. The goal of antihypertensive treatment is to reduce risk of cardiovascular morbidity and mortality. Apart from blood pressure lowering per se, also reducing the activities of the renin-angiotensin system and sympathetic nervous system appears to be important. Angiotensin II receptor blocker drugs (ARBs) have provided a useful class of anti-hypertensive drugs. Eprosartan is a relatively new ARB which is chemically distinct (non-biphenyl, non-tetrazole) from all other ARBs (biphenyl tetrazoles). An analysis has been made on available experimental and clinical data on eprosartan which not only is an effective and well tolerated antihypertensive agent, but also lowers the activities of the renin-angiotensin system and sympathetic nervous system. Experimental and pharmacokinetic studies on eprosartan have shown differences with the other ARBs. The distinct properties of this non-biphenyl, non-tetrazole ARB might be relevant in the effort to reduce cardiovascular risk, also beyond its blood pressure lowering capacity.
Keywords: Eprosartan, hypertension, sympathetic nervous system, renin angiotensin system
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
Volume: 6 Issue: 4
Author(s): P. J. Blankestijn and H. Rupp
Affiliation:
Keywords: Eprosartan, hypertension, sympathetic nervous system, renin angiotensin system
Abstract: Rationale. The goal of antihypertensive treatment is to reduce risk of cardiovascular morbidity and mortality. Apart from blood pressure lowering per se, also reducing the activities of the renin-angiotensin system and sympathetic nervous system appears to be important. Angiotensin II receptor blocker drugs (ARBs) have provided a useful class of anti-hypertensive drugs. Eprosartan is a relatively new ARB which is chemically distinct (non-biphenyl, non-tetrazole) from all other ARBs (biphenyl tetrazoles). An analysis has been made on available experimental and clinical data on eprosartan which not only is an effective and well tolerated antihypertensive agent, but also lowers the activities of the renin-angiotensin system and sympathetic nervous system. Experimental and pharmacokinetic studies on eprosartan have shown differences with the other ARBs. The distinct properties of this non-biphenyl, non-tetrazole ARB might be relevant in the effort to reduce cardiovascular risk, also beyond its blood pressure lowering capacity.
Export Options
About this article
Cite this article as:
Blankestijn J. P. and Rupp H., Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker, Cardiovascular & Hematological Agents in Medicinal Chemistry 2008; 6 (4) . https://dx.doi.org/10.2174/187152508785909500
DOI https://dx.doi.org/10.2174/187152508785909500 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metabolic and Cardiovascular Ageing Indices in Relation to Glycated Haemoglobin in Healthy and Diabetic Subjects
Current Aging Science Cilostazol in the Management of Atherosclerosis
Current Vascular Pharmacology Role of Micronutrients on Subclinical Atherosclerosis Micronutrients in Subclinical Atherosclerosis
Current Pharmaceutical Design Therapeutic Use of Calcitriol
Current Vascular Pharmacology Impact of Diabetes in Blood-Testis and Blood-Brain Barriers: Resemblances and Differences
Current Diabetes Reviews Trends in Metabolic Syndrome and Gene Networks in Human and Rodent Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Antihemostatic Strategies of Blood-Feeding Arthropods
Current Drug Targets - Cardiovascular & Hematological Disorders Early Hematoma Enlargement in Primary Intracerebral Hemorrhage
Current Drug Targets VIP as a Potential Therapeutic Agent in Gram Negative Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Pathophysiology of Heart Failure in Children: The Basics
Current Cardiology Reviews Dyslipidemia as a Risk Factor for Erectile Dysfunction
Current Medicinal Chemistry Low Birth Weight and Risk of Obesity - A Potential Problem for the Japanese People
Current Women`s Health Reviews Endothelium: A Target for Harmful Actions of Metals
Current Hypertension Reviews Oligonucleotide-Based Molecular Therapy for Restenosis after Angioplasty
Current Drug Targets TRH/TRH-R1 Receptor Signaling in the Brain Medulla as a Pathway of Vagally Mediated Gut Responses During the Cephalic Phase
Current Pharmaceutical Design Ezetimibe and Vascular Endothelial Function
Current Vascular Pharmacology Utility of Anti-Arrhythmic Medications in ‘Lone Atrial Fibrillation’
Current Pharmaceutical Design Essential Hypertension, Cerebral White Matter Pathology and Ischemic Stroke
Current Medicinal Chemistry DNA Methylation, An Epigenetic Mode of Gene Expression Regulation in Reproductive Science
Current Pharmaceutical Design Statin Therapy and New-onset Diabetes: Molecular Mechanisms and Clinical Relevance
Current Pharmaceutical Design